Meeting
2023 ASCO Genitourinary Cancers Symposium
Prognostic value of pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Authors
Zhipeng Wang
Department of Urology, West China Hospital, Sichuan University, Chengdu, China
Zhipeng Wang , Haoyang Liu , Jinge Zhao , Pengfei Shen , Hao Zeng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 198)
DOI
10.1200/JCO.2023.41.6_suppl.198
Abstract #
198
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo
Poster
2022 ASCO Genitourinary Cancers Symposium
Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.
First Author: Elahe A. Mostaghel
Poster
2021 ASCO Annual Meeting
Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.
First Author: Karim Fizazi
Poster
2020 Genitourinary Cancers Symposium
Prevalence and clinical impact of BRCA1/2 mutations in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Nieves Martinez Chanza